Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy

Micro-Abstract This study analyzes the clinical impact of NPM1 and FLT3 mutations in AML patients 65 years of age or older treated with cytotoxic chemotherapy at our institution. A total of 557 patients were retrospectively reviewed. No difference in survival was noted for patients with isolated FLT...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2013-08, Vol.13 (4), p.435-440
Main Authors: Daver, Naval, Liu Dumlao, Theresa, Ravandi, Farhad, Pierce, Sherry, Borthakur, Gautam, Pemmaraju, Naveen, Nazha, Aziz, Faderl, Stefan, Jabbour, Elias, Garcia-Manero, Guillermo, Cortes, Jorges, Kantarjian, Hagop, Quintás-Cardama, Alfonso
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Age Factors
Aged
Aged, 80 and over
Cytotoxic chemotherapy
Elderly
Female
FLT3
fms-Like Tyrosine Kinase 3 - genetics
fms-Like Tyrosine Kinase 3 - metabolism
Hematology, Oncology and Palliative Medicine
Humans
Incidence
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Male
Mutation
NPM1
Nuclear Proteins - genetics
Nuclear Proteins - metabolism
Prognosis
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract This study analyzes the clinical impact of NPM1 and FLT3 mutations in AML patients 65 years of age or older treated with cytotoxic chemotherapy at our institution. A total of 557 patients were retrospectively reviewed. No difference in survival was noted for patients with isolated FLT3 or NPM1 mutations. However, elderly AML patients who were NPM1 mutated and FLT3 wild type had significantly improved survival with cytotoxic chemotherapy.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2013.02.021